Daiichi Sankyo Executive and Leadership Team

Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, manages the strategic priorities and operational agenda of the executive office. Overseeing the flow of information to the Chief Executive Officer, the Chief of Staff To Chief Executive Officer ensures that leadership decisions are informed by comprehensive data and cross-departmental insights. This role involves coordinating high-level initiatives that span the entire organization, from drug discovery to commercialization. Kazuki Mori facilitates the execution of corporate strategy by aligning departmental goals with the vision of the Chief Executive Officer. By streamlining executive communications and project management, the Chief of Staff To Chief Executive Officer enhances the efficiency of the leadership team. Mori drives the implementation of strategic projects that support the company's mission, ensuring that the organization remains focused on delivering innovative medicines while navigating the complexities of the global pharmaceutical market.

Bruno Luiz de Vicente Cadastro, the Chief Financial Officer at Daiichi Sankyo, directs all global fiscal operations and capital allocation strategies. Managing the financial health of the organization, the Chief Financial Officer oversees long-term investment planning and risk mitigation frameworks essential for pharmaceutical research. This leadership role involves coordinating with international stakeholders to ensure fiscal transparency across all regional branches. By optimizing resource distribution, Bruno Luiz de Vicente Cadastro directly impacts the capacity for advanced drug discovery and delivery. The Chief Financial Officer maintains rigorous oversight of budgetary compliance, ensuring that financial structures support the overarching mission of providing innovative medicines to patients worldwide. Through precise financial modeling and strategic asset management, Cadastro secures the necessary capital to sustain the company's competitive position in the global pharmaceutical market while driving sustainable growth and operational efficiency.

Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, architects the operational frameworks that support corporate financial planning and departmental alignment. Overseeing the integration of financial data into strategic decision-making processes, the Manager, Chief Financial Officer Planning Department ensures that resource allocation remains consistent with the company's long-term pharmaceutical development goals. This role involves analyzing market trends to forecast fiscal requirements for drug discovery initiatives. Chloe Stern facilitates communication between the finance department and clinical research teams to streamline budgetary workflows. By refining internal planning protocols, the Manager, Chief Financial Officer Planning Department enhances the precision of financial reporting and operational accountability. Stern drives the implementation of advanced analytical tools to monitor performance metrics, ensuring that the organization maintains a robust financial foundation while pursuing breakthroughs in medicine across diverse global territories.

Naoki Hatakeyama, the President at Daiichi Sankyo, directs the overarching corporate strategy and operational excellence of the pharmaceutical business. Managing the company's growth trajectory, the President oversees the development of innovative medicines and the expansion of market reach across diverse international territories. This leadership role involves setting the vision for drug discovery and ensuring that the organization remains at the forefront of medical advancement. Naoki Hatakeyama facilitates the alignment of research, manufacturing, and commercial teams to achieve long-term business objectives. By fostering a culture of innovation and operational rigor, the President ensures that the company consistently delivers high-quality therapeutic solutions to patients. Hatakeyama drives the strategic partnerships and investment decisions that sustain the company's competitive position, ensuring that the organization remains a global leader in the pharmaceutical industry while addressing critical health challenges through advanced science and technology.

Suthas Thongprasert, the President at Daiichi Sankyo, manages the regional operational strategy and commercial performance within specific global markets. Overseeing the implementation of localized business models, the President ensures that the company's pharmaceutical products effectively reach patients in key geographic regions. This leadership role involves coordinating with local regulatory bodies and healthcare systems to optimize market access and product distribution. Suthas Thongprasert facilitates the integration of global corporate standards with regional market requirements to drive sustainable revenue growth. By focusing on operational efficiency and customer engagement, the President enhances the company's presence in competitive pharmaceutical landscapes. Thongprasert drives the execution of regional development plans, ensuring that the organization maintains a strong commitment to patient care and medical innovation while adapting to the unique regulatory and economic environments of the assigned operational territories.

John Harkins, the Senior Director, Chief of Staff, Global Oncology Clinical Development at Daiichi Sankyo, coordinates the strategic execution of clinical trials and oncology research programs. Managing the operational flow of development pipelines, the Senior Director, Chief of Staff, Global Oncology Clinical Development ensures that clinical milestones align with regulatory requirements and patient safety standards. This leadership role involves synchronizing cross-functional teams to accelerate the delivery of innovative cancer therapies. John Harkins facilitates high-level decision-making processes that determine the prioritization of drug candidates within the global oncology portfolio. By streamlining communication between research scientists and clinical operations, the Senior Director, Chief of Staff, Global Oncology Clinical Development optimizes the efficiency of the development lifecycle. Harkins drives the expansion of clinical capabilities, ensuring that the company maintains a leading edge in oncology research while addressing critical medical needs in international markets.

Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, manages the strategic integration of medical insights into the company's oncology product lifecycle. Overseeing the alignment of medical affairs with clinical development, the Global Oncology Medical Affairs Chief of Staff ensures that scientific data effectively supports the therapeutic value of new medicines. This role involves coordinating with global medical teams to disseminate critical research findings to healthcare providers and stakeholders. Caitlin Barnabo facilitates the operational planning necessary for successful product launches and ongoing medical education initiatives. By bridging the gap between clinical research and real-world application, the Global Oncology Medical Affairs Chief of Staff enhances the impact of the company's oncology portfolio. Barnabo drives the development of evidence-based strategies that improve patient outcomes, ensuring that medical affairs operations remain agile and responsive to evolving clinical needs across the global landscape.

Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, directs the implementation and maintenance of enterprise-wide digital systems that support pharmaceutical operations. Managing the infrastructure for global data management, the Chief of Staff & Global System Owner ensures that technological platforms remain secure, scalable, and compliant with international regulatory standards. This leadership role involves overseeing the integration of advanced software solutions to streamline drug discovery and supply chain processes. Kosuke Itagaki facilitates collaboration between IT departments and business units to optimize system performance and data accessibility. By standardizing global operational systems, the Chief of Staff & Global System Owner enhances organizational agility and decision-making speed. Itagaki drives the digital transformation strategy, ensuring that the company leverages cutting-edge technology to maintain its competitive advantage in the pharmaceutical industry while supporting seamless operations across all regional offices.